Germany - Drugs

Description

This notice does not concern the award of a public contract within the meaning of the Public Procurement Coordination Directive (2014/24/EU) or antitrust law. In the interest of providing the broadest possible information to interested pharmaceutical companies, this notice is published in the Supplement to the Official Journal of the European Union. The procedural designation "open procedure" (Section IV.1.1) used in the text of this announcement is due to the requirements of the announcement form. Neither this nor the use of the "TED" medium is associated with any submission to procurement law regulations, the application of which is not mandatory by virtue of the law or procurement regulations. This is a framework agreement with an option to join, which relates to various active ingredients.
The subject of the agreement are drugs containing the active ingredient abiraterone. The contract covers drugs containing the active ingredient combination aclidinium cation + formoterol. The subject of the Agreement are medicinal products containing the active ingredient aripiprazole in a parenteral dosage form. The subject of the Agreement are medicinal products containing the active ingredient denosumab in the administration form of pre-filled syringes. The subject of the Agreement are medicinal products containing the active ingredient flupentixol in the dosage form solution for injection. The subject of the Agreement are medicinal products containing the active ingredient fluvastatin in the sustained-release tablet dosage form. The Contractual Products are medicinal products containing the active substance lapatinib. The Contractual Products are medicinal products containing the active substance methocarbamol in the active strength of 1500 mg and in the package size of 12 units. The Contractual Products are medicinal products containing the active ingredient midazolam hydrochloride in the dosage form ready-to-fill syringes. The subject of the Agreement are medicinal products containing the active ingredient nitisinone in the pharmaceutical form of hard capsules. The subject of the Agreement are medicinal products containing the active ingredient nitrofurantoin. The subject of the Agreement are medicinal products containing the active ingredient oseltamivir. The subject of the Agreement are medicinal products containing the active ingredient progesterone in the dosage form vaginal capsules. The subject of the Agreement are medicinal products containing the active ingredient combination timolol + latanoprost in the dosage form single-dose pipettes. The subject of the Agreement are medicinal products containing the active ingredient tranylcypromine. The contract covers medicinal products containing the active ingredient triptorelin embonate.

Opportunity closing date

01 May 2025

Value of contract

£0-100k